A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models

Kader Yagiz, Maria E. Rodriguez-Aguirre, Fernando Lopez Espinoza, Tiffany T. Montellano, Daniel Mendoza, Leah A. Mitchell, Carlos E. Ibanez, Noriyuki Kasahara, Harry E. Gruber, Douglas J. Jolly, Joan M. Robbins

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term immune-mediated survival. Phase 1 Toca 511 and Toca FC (extended-release 5-FC) clinical trials in patients with recurrent high-grade glioma show durable complete responses and promising survival data compared to historic controls. The work described herein served to expand on our earlier findings in two models of metastatic colorectal carcinoma (mCRC). Intravenous (i.v.) delivery of Toca 511 resulted in substantial tumor-selective uptake of vector into metastatic lesions. Subsequent treatment with 5-FC resulted in tumor shrinkage, improved survival, and immune memory against future rechallenge with the same CT26 CRC cell line. Similar results were seen in a brain metastasis model of mCRC. Of note, 5-FC treatment resulted in a significant decrease in myeloid-derived suppressor cells (MDSCs) in mCRC tumors in both the liver and brain. These results support the development of Toca 511 and Toca FC as a novel immunotherapeutic approach for patients with mCRC. A phase 1 study of i.v. Toca 511 and Toca FC in solid tumors, including mCRC, is currently underway (NCT02576665).

Original languageEnglish (US)
Pages (from-to)14-26
Number of pages13
JournalMolecular Therapy - Oncolytics
Volume8
DOIs
StatePublished - Mar 30 2018

Fingerprint

Cytosine Deaminase
Flucytosine
Colorectal Neoplasms
Neoplasms
Survival
Brain
Therapeutics
Brain Neoplasms
Glioma
Fluorouracil
Clinical Trials
Neoplasm Metastasis
Cell Line
Liver

Keywords

  • 5-FU
  • chemoimmunotherapy
  • durable response
  • immunotherapy
  • mCRC
  • MDSC
  • retroviral vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Yagiz, K., Rodriguez-Aguirre, M. E., Lopez Espinoza, F., Montellano, T. T., Mendoza, D., Mitchell, L. A., ... Robbins, J. M. (2018). A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Molecular Therapy - Oncolytics, 8, 14-26. https://doi.org/10.1016/j.omto.2017.12.001

A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. / Yagiz, Kader; Rodriguez-Aguirre, Maria E.; Lopez Espinoza, Fernando; Montellano, Tiffany T.; Mendoza, Daniel; Mitchell, Leah A.; Ibanez, Carlos E.; Kasahara, Noriyuki; Gruber, Harry E.; Jolly, Douglas J.; Robbins, Joan M.

In: Molecular Therapy - Oncolytics, Vol. 8, 30.03.2018, p. 14-26.

Research output: Contribution to journalArticle

Yagiz, K, Rodriguez-Aguirre, ME, Lopez Espinoza, F, Montellano, TT, Mendoza, D, Mitchell, LA, Ibanez, CE, Kasahara, N, Gruber, HE, Jolly, DJ & Robbins, JM 2018, 'A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models', Molecular Therapy - Oncolytics, vol. 8, pp. 14-26. https://doi.org/10.1016/j.omto.2017.12.001
Yagiz, Kader ; Rodriguez-Aguirre, Maria E. ; Lopez Espinoza, Fernando ; Montellano, Tiffany T. ; Mendoza, Daniel ; Mitchell, Leah A. ; Ibanez, Carlos E. ; Kasahara, Noriyuki ; Gruber, Harry E. ; Jolly, Douglas J. ; Robbins, Joan M. / A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. In: Molecular Therapy - Oncolytics. 2018 ; Vol. 8. pp. 14-26.
@article{69827ed95c19434594e9fc9e390438f4,
title = "A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models",
abstract = "Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term immune-mediated survival. Phase 1 Toca 511 and Toca FC (extended-release 5-FC) clinical trials in patients with recurrent high-grade glioma show durable complete responses and promising survival data compared to historic controls. The work described herein served to expand on our earlier findings in two models of metastatic colorectal carcinoma (mCRC). Intravenous (i.v.) delivery of Toca 511 resulted in substantial tumor-selective uptake of vector into metastatic lesions. Subsequent treatment with 5-FC resulted in tumor shrinkage, improved survival, and immune memory against future rechallenge with the same CT26 CRC cell line. Similar results were seen in a brain metastasis model of mCRC. Of note, 5-FC treatment resulted in a significant decrease in myeloid-derived suppressor cells (MDSCs) in mCRC tumors in both the liver and brain. These results support the development of Toca 511 and Toca FC as a novel immunotherapeutic approach for patients with mCRC. A phase 1 study of i.v. Toca 511 and Toca FC in solid tumors, including mCRC, is currently underway (NCT02576665).",
keywords = "5-FU, chemoimmunotherapy, durable response, immunotherapy, mCRC, MDSC, retroviral vector",
author = "Kader Yagiz and Rodriguez-Aguirre, {Maria E.} and {Lopez Espinoza}, Fernando and Montellano, {Tiffany T.} and Daniel Mendoza and Mitchell, {Leah A.} and Ibanez, {Carlos E.} and Noriyuki Kasahara and Gruber, {Harry E.} and Jolly, {Douglas J.} and Robbins, {Joan M.}",
year = "2018",
month = "3",
day = "30",
doi = "10.1016/j.omto.2017.12.001",
language = "English (US)",
volume = "8",
pages = "14--26",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models

AU - Yagiz, Kader

AU - Rodriguez-Aguirre, Maria E.

AU - Lopez Espinoza, Fernando

AU - Montellano, Tiffany T.

AU - Mendoza, Daniel

AU - Mitchell, Leah A.

AU - Ibanez, Carlos E.

AU - Kasahara, Noriyuki

AU - Gruber, Harry E.

AU - Jolly, Douglas J.

AU - Robbins, Joan M.

PY - 2018/3/30

Y1 - 2018/3/30

N2 - Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term immune-mediated survival. Phase 1 Toca 511 and Toca FC (extended-release 5-FC) clinical trials in patients with recurrent high-grade glioma show durable complete responses and promising survival data compared to historic controls. The work described herein served to expand on our earlier findings in two models of metastatic colorectal carcinoma (mCRC). Intravenous (i.v.) delivery of Toca 511 resulted in substantial tumor-selective uptake of vector into metastatic lesions. Subsequent treatment with 5-FC resulted in tumor shrinkage, improved survival, and immune memory against future rechallenge with the same CT26 CRC cell line. Similar results were seen in a brain metastasis model of mCRC. Of note, 5-FC treatment resulted in a significant decrease in myeloid-derived suppressor cells (MDSCs) in mCRC tumors in both the liver and brain. These results support the development of Toca 511 and Toca FC as a novel immunotherapeutic approach for patients with mCRC. A phase 1 study of i.v. Toca 511 and Toca FC in solid tumors, including mCRC, is currently underway (NCT02576665).

AB - Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term immune-mediated survival. Phase 1 Toca 511 and Toca FC (extended-release 5-FC) clinical trials in patients with recurrent high-grade glioma show durable complete responses and promising survival data compared to historic controls. The work described herein served to expand on our earlier findings in two models of metastatic colorectal carcinoma (mCRC). Intravenous (i.v.) delivery of Toca 511 resulted in substantial tumor-selective uptake of vector into metastatic lesions. Subsequent treatment with 5-FC resulted in tumor shrinkage, improved survival, and immune memory against future rechallenge with the same CT26 CRC cell line. Similar results were seen in a brain metastasis model of mCRC. Of note, 5-FC treatment resulted in a significant decrease in myeloid-derived suppressor cells (MDSCs) in mCRC tumors in both the liver and brain. These results support the development of Toca 511 and Toca FC as a novel immunotherapeutic approach for patients with mCRC. A phase 1 study of i.v. Toca 511 and Toca FC in solid tumors, including mCRC, is currently underway (NCT02576665).

KW - 5-FU

KW - chemoimmunotherapy

KW - durable response

KW - immunotherapy

KW - mCRC

KW - MDSC

KW - retroviral vector

UR - http://www.scopus.com/inward/record.url?scp=85044862244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044862244&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2017.12.001

DO - 10.1016/j.omto.2017.12.001

M3 - Article

AN - SCOPUS:85044862244

VL - 8

SP - 14

EP - 26

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

ER -